Clinical Trial Site

Durham, North Carolina 27713

6 studies enrolling now · 17 studies all time

What they study most

ATTR Amyloidosis, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Hereditary, Amyloidosis, Hereditary, Transthyretin-Related, Atypical Hemolytic Uremic Syndrome (aHUS), Cerebral Amyloid Angiopathy, Cutaneous Sarcoidosis, Dravet Syndrome, Familial Amyloid Polyneuropathies, Familial Amyloidotic Cardiomyopathy (FAC), Familial Transthyretin Cardiac Amyloidosis

Studies at this site

• A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris — Recruiting now
• ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) — Recruiting now
• Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) — Recruiting now
• A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON) — Recruiting now
• Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution — Running, not enrolling
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Enrolling by invitation
• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Running, not enrolling
• A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis — Running, not enrolling
• A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis — Completed
• APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis — Completed
• Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) — Completed
• Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery — Stopped early
• ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) — Completed
• DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis — Completed